#London #United Kingdom #diagnostics #Virax Biolabs #Iain Miller

Virax Biolabs Appoints Dr. Iain Miller as Independent Director

Virax Biolabs Group Limited, a pioneering biotechnology firm specializing in the detection of immune responses, proudly announces the addition of Dr. Iain Miller to its Board of Directors as an Independent Director, effective July 29, 2025. This appointment signifies an important milestone in Virax's strategy to enhance its commercial operations and expand its innovative immune profiling platform.

Dr. Miller takes over from Yair Erez, who stepped down to pursue other professional interests. The leadership at Virax expresses gratitude to Mr. Erez for his significant contributions during his tenure. Dr. Miller brings with him over three decades of extensive experience in the diagnostics and MedTech industries, with a robust background that includes key positions at prominent organizations such as GE Healthcare and bioMérieux. His vast experience spans both the UK and US markets, where he has successfully launched and led multiple MedTech ventures, including Presymptom Health, a spinout from the UK's Ministry of Defence.

Under Dr. Miller's leadership, Presymptom Health created a groundbreaking diagnostic tool called InfectiClear®, aimed at addressing infectious diseases. His dedication to the field extends to his active participation in the UK's National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee, along with contributing to significant innovation initiatives at NHS England and the Medicine and Healthcare products Regulatory Agency (MHRA).

Dr. Miller holds an impressive educational background, with a PhD in BioEngineering from the University of Strathclyde, an MBA from the University of Edinburgh, and a BSc in Physics with Electronics from the University of Glasgow. His prolific contributions to diagnostic innovation through publications further solidify his expertise in the field. Virax looks forward to leveraging Dr. Miller's commercial, technical, and regulatory insights as the company seeks to broaden its impact within the diagnostic landscape, particularly in immune profiling.

James Foster, CEO of Virax Biolabs, stated, “We are thrilled to welcome Dr. Iain Miller to our board at such a crucial juncture for our company. His extensive leadership experience across both private and public sectors, coupled with invaluable diagnostics knowledge, will be critical as we work on advancing our immune profiling platform.” Foster emphasized that the addition of Dr. Miller comes as Virax continues its progress with its Research-Use-Only (RUO) products and aims to evolve into In Vitro Diagnostic (IVD) development.

Expressing his enthusiasm about the new role, Dr. Miller commented, “Joining the Virax Board at a time so ripe with opportunity is exciting. The innovative immune profiling platform is poised to redefine monitoring chronic and post-viral conditions. I am eager to support the team in achieving this vision.”

As Virax Biolabs steers toward transformative advancements in diagnostic technology, the company remains focused on developing T-Cell-based testing methods, targeting the identification of immune responses associated with viral diseases, such as Long COVID and other chronic immune-related conditions. With Dr. Miller’s appointment and the dedication to innovation in immune profiling, Virax Biolabs is poised for significant growth and impact in the biotechnology sector.

For more information about Virax Biolabs and their ongoing projects, please visit Virax Biolabs.